Patient Selection Factors for GPRC5D-Targeted Therapies
Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.
EP: 1.GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma
EP: 2.Real-World Efficacy of GPRC5D Bispecifics vs Clinical Trials
EP: 3.Patient Selection Factors for GPRC5D-Targeted Therapies
EP: 4.Patient Subgroup Outcomes with GPRC5D Bispecifics
EP: 5.Biomarkers and Clinical Features Influencing GPRC5D Bispecific Initiation
EP: 6.Integration of GPRC5D-Targeted Therapies in RRMM Treatment
EP: 7.Prevalent Safety Concerns in Community Settings
EP: 8.Challenging Adverse Events with GPRC5D-Targeted Therapies
EP: 9.Long-Term Monitoring Protocols for Bispecific Therapy Complications
EP: 10.Proactive Steps for Mitigating GPRC5D Therapy Adverse Events
EP: 11.Logistical Barriers in Implementing GPRC5D-Targeted Therapies
EP: 12.Healthcare Resource Utilization Impact of GPRC5D-Targeted Therapies
EP: 13.Resources Needed for Enhanced Bispecific Implementation
EP: 14.Areas for Improvement in Real-World GPRC5D-Targeted Therapy Application
EP: 15.Future Impact of GPRC5D-Targeted Therapies on RRMM Treatment
EP: 16.Unmet Needs and Future Directions for GPRC5D Bispecific Therapy
- What factors guide your selection of patients for GPRC5D-targeted therapies in the relapsed/refractory setting?
- How do prior lines of therapy affect the selection process?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
